Sight Sciences Stock News

Sight Sciences, Inc. (NASDAQ:SGHT ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Paul Badawi - Chief Executive

Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 2.13% and 5.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

MENLO PARK, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improv

MENLO PARK, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on creating innovative solutions intended to transform care and improve

MENLO PARK, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to tran

Sight Sciences went public in July 2021, raising $240 million in an IPO. The firm develops and sells various surgical devices for treatment of glaucoma and dry eye conditions.

Sight Sciences, Inc. (NASDAQ:SGHT ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Paul Badawi - Co-Founder & Chief Executive Offic

Sight Sciences (SGHT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Sight Sciences, Inc (NASDAQ:SGHT ) Q1 2022 Results Conference Call May 10, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Paul Badawi - Co-Founder and Chief Executive Officer

MENLO PARK, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on creating innovative solutions intended to transform care and improve

MENLO PARK, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and impro

Sight Sciences, Inc. (SGHT) CEO Paul Badawi on Q4 2021 Results - Earnings Call Transcript

MENLO PARK, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the quarter and year ended December 31, 2021, after the market close on Thursday, March 24, 2022. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Educational campaign aims to raise awareness among the optometric community of minimally invasive glaucoma surgery (MIGS) as an earlier surgical intervention for glaucoma Educational campaign aims to raise awareness among the optometric community of minimally invasive glaucoma surgery (MIGS) as an earlier surgical intervention for glaucoma

MENLO PARK, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ: SGHT ), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients'' lives, today announced the launch of its "Don''t Wait for Too Late" educational campaign designed to raise awareness among the optometric community of minimally invasive glaucoma surgery (MIGS) as an earlier surgical intervention for glaucoma. Glaucoma, known as the silent thief of sight, is the world''s leading cause of irreversible blindness. Vision loss from glaucoma cannot be recovered, so early intervention is critical to preserving sight. Traditionally, early intervention in glaucoma has been limited primarily to prescription eye drops, with surgery reserved for more severe cases. However, prescription medications are only effective if they are taken as prescribed, and compliance can be a major issue. Today, advances in glaucoma management with MIGS are presenting new opportunities for early surgical intervention in patients with mild to moderate glaucoma.